[
  {
    "report_key": "2026:q1",
    "period_label": "2026 Q1",
    "date": "2026-05-12",
    "title": "Kvartalsrapport Q1 2026",
    "original_title": "Kvartalsrapport Q1 2026: Orviglance® närmar sig transformerande milstolpar",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b69e833ef3fd325c14b44bfc91e2a9f2f&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2026,
    "quarter": "q1",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
        "title": "Kvartalsrapport Q1 2026",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/afc93eedfdc0d8248fb35c5930da0290d",
        "date": "2026-05-12",
        "period": "2026-q1",
        "form_type": "interim-report",
        "report_key": "2026:q1",
        "filename": "Ascelia_Pharma_Q1_2026_SE.pdf",
        "text_chars": 46956,
        "sha256": "bc77cf42cc12a08c198dfec56f258a6d51ff4f27c64f8bbb0473f328f0c7adbb",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
            "chars": 46956
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:annual",
    "period_label": "2025 Årsredovisning",
    "date": "2026-04-09",
    "title": "Årsredovisning 2025",
    "original_title": "Årsredovisning 2025: Orviglance NDA inskickad till FDA, PDUFA datum satt till Juli 2026",
    "category": "Bokslut och Verksamhetsberättelse",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b09d01f06d38330f139cdb8b92b3580f2&lang=sv&src=listed",
    "language": "sv",
    "report_type": "annual-report",
    "fiscal_year": 2025,
    "quarter": "annual",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-arsredovisning-2025",
        "title": "Årsredovisning 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a616779d0c144e5181631d424d0a1c6ac",
        "date": "2026-04-09",
        "period": "2025-annual",
        "form_type": "annual-report",
        "report_key": "2025:annual",
        "filename": "Ascelia_Pharma_Arsredovisning_2025.pdf",
        "text_chars": 259489,
        "sha256": "5a1e670cb79ae0cf609fae8beb4c9c0cd92a47ee9f1a4fe17de375ace763b116",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
            "chars": 179252
          },
          {
            "number": 2,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
            "chars": 80235
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q4",
    "period_label": "2025 Q4",
    "date": "2026-02-05",
    "title": "Kvartalsrapport Q4 2025",
    "original_title": "Bokslutskommuniké och Q4 2025: FDA accepterar Orviglance NDA-ansökan för granskning",
    "category": "Bokslutskommuniké",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b8edbdd8cff5d787e93ebd817fa866254&lang=sv&src=listed",
    "language": "sv",
    "report_type": "year-end-report",
    "fiscal_year": 2025,
    "quarter": "q4",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
        "title": "Kvartalsrapport Q4 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/ac95cf882f063fb0fdbf3803d3a2928d9",
        "date": "2026-02-05",
        "period": "2025-q4",
        "form_type": "year-end-report",
        "report_key": "2025:q4",
        "filename": "Ascelia_Pharma_Q4_2025.pdf",
        "text_chars": 52909,
        "sha256": "95cbd61adaaf2e96b19e143dc511b14d93d090c3f78a9d27f02ac8269d8d427d",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
            "chars": 52909
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q3",
    "period_label": "2025 Q3",
    "date": "2025-11-05",
    "title": "Kvartalsrapport Q3 2025",
    "original_title": "Delårsrapport Q3 2025: Orviglance NDA-ansökan inskickad till FDA",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b4c0ac7b24fd0b3e05b58b7113c01f556&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2025,
    "quarter": "q3",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
        "title": "Kvartalsrapport Q3 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a0bd38d3d3473553aaf09a09e9a7bc202",
        "date": "2025-11-05",
        "period": "2025-q3",
        "form_type": "interim-report",
        "report_key": "2025:q3",
        "filename": "Ascelia_Pharma_Q3_2025_SE.pdf",
        "text_chars": 51996,
        "sha256": "e1f87ea0d9d73d455a94bd34665de4a24a52e74000297f0b17796b69270b31f7",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
            "chars": 51996
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q2",
    "period_label": "2025 Q2",
    "date": "2025-08-21",
    "title": "Kvartalsrapport Q2 2025",
    "original_title": "Halvårsrapport 2025: Orviglance inlämning av NDA-ansökana närmar sig",
    "category": "Halvårsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b4e2b23a5f5fff25b28ac4cadfe8da712&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2025,
    "quarter": "q2",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
        "title": "Kvartalsrapport Q2 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a3d4633d3bd8c209d4e385149d182661e",
        "date": "2025-08-21",
        "period": "2025-q2",
        "form_type": "interim-report",
        "report_key": "2025:q2",
        "filename": "Ascelia_Pharma_Q2_2025_SE.pdf",
        "text_chars": 54358,
        "sha256": "51ee868cb16beb7bcaa6aeed20fdcdc0aac937843ddc0becff6f3b78d319e399",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
            "chars": 54358
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q1",
    "period_label": "2025 Q1",
    "date": "2025-05-16",
    "title": "Kvartalsrapport Q1 2025",
    "original_title": "Kvartalsrapport Q1 2025: Positivt utfall från FDA-möte om Orviglance före NDA-ansökan",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b9ea9b36d4b231c94af03a4b9d924ff90&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2025,
    "quarter": "q1",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
        "title": "Kvartalsrapport Q1 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/ab0309755cd233bb89a6ff3debac9b3f2",
        "date": "2025-05-16",
        "period": "2025-q1",
        "form_type": "interim-report",
        "report_key": "2025:q1",
        "filename": "Ascelia_Pharma_Q1_2025_SE_250516.pdf",
        "text_chars": 48845,
        "sha256": "788877cceef954e263a215c074756092b5a865bf4d07f9c35a944cf288d9ed08",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
            "chars": 48845
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:annual",
    "period_label": "2024 Årsredovisning",
    "date": "2025-04-11",
    "title": "Årsredovisning 2024",
    "original_title": "Årsredovisning 2024: Orviglance går vidare till registreringsfasen efter framgångsrikt slutförande av fas 3-studie",
    "category": "Bokslut och Verksamhetsberättelse",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b0f00ac372dd574182515b9261b30e206&lang=sv&src=listed",
    "language": "sv",
    "report_type": "annual-report",
    "fiscal_year": 2024,
    "quarter": "annual",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-arsredovisning-2024",
        "title": "Årsredovisning 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a00c6afb766258f9d091d3cc61d2ade0e",
        "date": "2025-04-11",
        "period": "2024-annual",
        "form_type": "annual-report",
        "report_key": "2024:annual",
        "filename": "Ascelia_Pharma_Arsredovisning_2024.pdf",
        "text_chars": 263104,
        "sha256": "2523d6c1016f772ca129ae42a2ad5fab28b17431c274be29585eabc27293adef",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
            "chars": 176500
          },
          {
            "number": 2,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
            "chars": 86602
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q4",
    "period_label": "2024 Q4",
    "date": "2025-02-07",
    "title": "Kvartalsrapport Q4 2024",
    "original_title": "Q4 och Bokslutskommuniké 2024: Slutförande av fullständig studierapport förstärker framgångsrika resultat av SPARKLE fas-3 studien",
    "category": "Bokslutskommuniké",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b3632030a6629982bd17878b9cb9d4115&lang=sv&src=listed",
    "language": "sv",
    "report_type": "year-end-report",
    "fiscal_year": 2024,
    "quarter": "q4",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
        "title": "Kvartalsrapport Q4 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a3c8b1c0607ebd46fb8d7adda42ef6d0f",
        "date": "2025-02-07",
        "period": "2024-q4",
        "form_type": "year-end-report",
        "report_key": "2024:q4",
        "filename": "Ascelia_Pharma_Q4_2024_SE.pdf",
        "text_chars": 54352,
        "sha256": "fdaa7eaf56e45a1868026ced37edcc3820a1f2e88f14667d1f167bcc54654c69",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
            "chars": 54352
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q3",
    "period_label": "2024 Q3",
    "date": "2024-11-07",
    "title": "Kvartalsrapport Q3 2024",
    "original_title": "Kvartalsrapport Q3: Framgångsrikt utfall av företrädesemission om 105 MSEK förlänger kassalikviditeten till sent 2025",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bc21dfc30d3540aeb444935f06e6972d2&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2024,
    "quarter": "q3",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
        "title": "Kvartalsrapport Q3 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a4a60435dc93d1eb08890a823fc155e1f",
        "date": "2024-11-07",
        "period": "2024-q3",
        "form_type": "interim-report",
        "report_key": "2024:q3",
        "filename": "Ascelia_Pharma_Q3_2024_SE.pdf",
        "text_chars": 54708,
        "sha256": "8051e40d1e7a5358323786a691f7f055eb5418fced2269b42df90f11a851432a",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
            "chars": 54708
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q2",
    "period_label": "2024 Q2",
    "date": "2024-08-15",
    "title": "Kvartalsrapport Q2 2024",
    "original_title": "Halvårsrapport 2024: Orviglance slutför den kliniska utvecklingen med framgångsrik fas 3-studie",
    "category": "Halvårsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b4956867fb8f131ceadffce5286183d8b&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2024,
    "quarter": "q2",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
        "title": "Kvartalsrapport Q2 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a50f6e76c1a4cfe9dcc6f3f7e6bdbe06f",
        "date": "2024-08-15",
        "period": "2024-q2",
        "form_type": "interim-report",
        "report_key": "2024:q2",
        "filename": "Ascelia_Pharma_Q2_2024_SE_240815.pdf",
        "text_chars": 54245,
        "sha256": "3800d27e1020e4c18138d9c5d2dce7d120b63cdb49e8c8160803a8c825df84dd",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
            "chars": 54245
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q1",
    "period_label": "2024 Q1",
    "date": "2024-05-16",
    "title": "Kvartalsrapport Q1 2024",
    "original_title": "Kvartalsrapport Q1: Primärt effektmått uppnått med starka headline-resultat i fas 3-studien med Orviglance",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bdf1b0389fdef135169b56502e24911a1&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2024,
    "quarter": "q1",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
        "title": "Kvartalsrapport Q1 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a4b3a34203db8ddb9ccdc47c88279ba3f",
        "date": "2024-05-16",
        "period": "2024-q1",
        "form_type": "interim-report",
        "report_key": "2024:q1",
        "filename": "Ascelia_Pharma_Q1_2024_SE_240516.pdf",
        "text_chars": 46622,
        "sha256": "34b7f120f5dd9d0b0db38a27f86da644f9b0e04f8602984926e85f239891ff75",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
            "chars": 46622
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2023:annual",
    "period_label": "2023 Årsredovisning",
    "date": "2024-04-08",
    "title": "Årsredovisning 2023",
    "original_title": "Årsredovisning 2023: Solida framsteg med slutförd patientrekrytering till Orviglance fas 3 och förväntat headline-resultat i maj 2024",
    "category": "Bokslut och Verksamhetsberättelse",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bda2a301b6d24ae2e9bff4ed8c3672a23&lang=sv&src=listed",
    "language": "sv",
    "report_type": "annual-report",
    "fiscal_year": 2023,
    "quarter": "annual",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-arsredovisning-2023",
        "title": "Årsredovisning 2023",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a6f550d3eb9eb04ee2ed2f5461835f868",
        "date": "2024-04-08",
        "period": "2023-annual",
        "form_type": "annual-report",
        "report_key": "2023:annual",
        "filename": "Ascelia_Pharma_Arsredovisning_2023.pdf",
        "text_chars": 257086,
        "sha256": "61df62f48fed6af7dad70c02e6d424aa5f716dfc01520f056e23a6fea9714f53",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
            "chars": 176330
          },
          {
            "number": 2,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
            "chars": 80754
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2023:q4",
    "period_label": "2023 Q4",
    "date": "2024-02-09",
    "title": "Kvartalsrapport Q4 2023",
    "original_title": "Q4 och bokslutskommuniké 2023: Stärkt finansiell position inför headline-resultat i maj för den kliniska fas-3 studien SPARKLE",
    "category": "Bokslutskommuniké",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bc37e6c44f6bae3b8eee4a241226664ea&lang=sv&src=listed",
    "language": "sv",
    "report_type": "year-end-report",
    "fiscal_year": 2023,
    "quarter": "q4",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
        "title": "Kvartalsrapport Q4 2023",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a83aa3ac4584a5ed5eb687522f6c53272",
        "date": "2024-02-09",
        "period": "2023-q4",
        "form_type": "year-end-report",
        "report_key": "2023:q4",
        "filename": "Ascelia_Pharma_Q4_2023_SE.pdf",
        "text_chars": 50975,
        "sha256": "7ba68666b6aca63ae4df5542b8ade44ec73c8873506549553a8a48aa897714af",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
            "chars": 50975
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2023:q3",
    "period_label": "2023 Q3",
    "date": "2023-11-08",
    "title": "Kvartalsrapport Q3 2023",
    "original_title": "KVARTALSRAPPORT Q3 2022: Den ny utläsning av bilderna från fas 3-studien SPARKLE fortskrider enligt planen",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=be1dbee39a2436abecbee0763eee739d4&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2023,
    "quarter": "q3",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
        "title": "Kvartalsrapport Q3 2023",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/ad8debcc95fb9ebaf2a39f4e11f4cbe83",
        "date": "2023-11-08",
        "period": "2023-q3",
        "form_type": "interim-report",
        "report_key": "2023:q3",
        "filename": "Ascelia_Pharma_Q3_2023_SE_231108.pdf",
        "text_chars": 48935,
        "sha256": "29876da6ecf825218e5bc5c11982d65e0dd23950c7f76e2dc9b8d217165a6c2f",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
            "chars": 48935
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2023:q2",
    "period_label": "2023 Q2",
    "date": "2023-08-18",
    "title": "Kvartalsrapport Q2 2023",
    "original_title": "Halvårsrapport 2023: Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE",
    "category": "Halvårsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b699d093efd0878ee0e9cad791c2bca65&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2023,
    "quarter": "q2",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
        "title": "Kvartalsrapport Q2 2023",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a8e47626daae85e5d3f09d934c5a78640",
        "date": "2023-08-18",
        "period": "2023-q2",
        "form_type": "interim-report",
        "report_key": "2023:q2",
        "filename": "Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf",
        "text_chars": 50492,
        "sha256": "596d2844d6a7ea6a7ea215ff21620020f1af3d0b026f448b5ec9c8428fed90dd",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
            "chars": 50492
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2023:q1",
    "period_label": "2023 Q1",
    "date": "2023-05-11",
    "title": "Kvartalsrapport Q1 2023",
    "original_title": "KVARTALSRAPPORT Q1 2023: Fas 3 studien för Orviglance, SPARKLE, sista patientens sista besök (Last Patient Last Visit, LPLV) har avslutats",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b4f9bfcf2b2288a03455413497a756177&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2023,
    "quarter": "q1",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
        "title": "Kvartalsrapport Q1 2023",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a38094033dd5f7565b9bd71081841a20d",
        "date": "2023-05-11",
        "period": "2023-q1",
        "form_type": "interim-report",
        "report_key": "2023:q1",
        "filename": "Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf",
        "text_chars": 40790,
        "sha256": "f9ad05d7bcd9de92ec45b89b29b4bb1304970e81881728c5adc66d210f6a6fba",
        "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
        "absolute_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
        "txt_url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/ascelia-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
            "chars": 40790
          }
        ]
      }
    ],
    "alternatives": []
  }
]